BridgeBio's Investigation Drug Outperforms Standard Therapy In Rare Calcium Disorder

benzinga.com/news/health-care/25/10/48506974/bridgebios-investigation-drug-outperforms-standard-therapy-in-rare-calcium-disorder

BridgeBio Pharma Inc. (NASDAQ:BBIO) released topline results from the CALIBRATE Phase 3 study of encaleret in autosomal dominant hypocalcemia type 1 (ADH1) on Wednesday.
ADH1 is a genetic disorder causing low blood calcium with inappropriately low parathyroid hormone (PTH) levels.
BBIO…

This story appeared on benzinga.com, 2025-10-29 18:22:58.
The Entire Business World on a Single Page. Free to Use →